Biotechnology · Laboratory Equipment
Takara Bio: Products & infrastructure
Takara Bio has 8 clinical trials on record, 3 under way.
Data updated Nov 21, 2026 · Back to the company report
Products
Takara Bio has 8 clinical trials on record, 3 under way.
8clinical trials
3trials under way
1in phase 3
Clinical trialsthe studies it sponsors or works on, per ClinicalTrials.gov
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarc…
phase 3 · under way · 5 participants · Synovial Sarcomas
Jan 2026
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
phase 1 · under way · 36 participants · Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV
Sep 2017
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
phase 2 · completed · 8 participants · Synovial Sarcoma
Sep 2017
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
phase 2 · under way · 21 participants · Lymphoblastic Leukemia, Acute Adult
Jun 2017
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
phase 2 · completed · 28 participants · Melanoma Stage III; Melanoma Stage IV
May 2017
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
phase 1 · completed · 6 participants · Solid Tumor
Jun 2015
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
phase 2 · completed · 46 participants · Malignant Melanoma
Apr 2014
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
phase 1 · completed · 28 participants · Refractory Head and Neck Cancer; Squamous Cell Carcinoma, Skin; Carcinoma of th…
Aug 2009
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
